



The Results of the use of Teriparatide for Prevention in both Vertebral and Non-Vertebral Fractures in Postmenopausal Osteoporosis

A Systematic Review of Literature

Essay

Submitted for Partial Fulfillment of Master Degree in Orthopaedic Surgery

Presented by

Khalid Nabil Youssef Abdu

(M.B.B.Ch., Ain Shams University)

Supervised by:

Prof. Mohamed Abdel Salam Wafa

Professor of Orthopedic Surgery

The Head of the Spine surgery unit

Faculty of Medicine – Ain Shams University

Dr. Tameem Mohamed El-Khateeb

Lecturer of Orthopedic Surgery

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2016



نتائج إستخدام عقار التريباراتايد للوقاية من كسور العمود الفقري وكسور غير العمود الفقري لحالات هشاشة العظام التى تصيب الإناث فى فترة ما بعد انقطاع الطمث

مراجعة منهجية لما تم نشره

رسالة

في جراحة العظام

مقدمة من

طبيب / خالد نبيل يوسف عبده

بكالوريوس الطب والجراحة- جامعة عين شمس

تحت إشراف

الأستاذ الدكتور / محمد عبد السلام وفا

أستاذ جراحة العظام

رئيس وحدة جراحات العمود الفقري

كلية الطب جامعة عين شمس

الدكتور / تميم محمد شفيق الخطيب

مدرس جراحة العظام

كلية الطب جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٦



Acknowledgement

First and forever, thanks to "ALLAH", the Almighty, the Gracious, who give us the knowledge and have given me the strength to achieve my work,

*I wish to express my deepest appreciation and gratitude to **Prof. Mohamed Abdel Salam Wafa**, Professor of Orthopedic Surgery, The Head of the Spine surgery unit, Faculty of Medicine – Ain Shams University, for his guidance, support, for introducing me in to this exciting field of research.*

*I hope to express my deepest gratitude to **Dr. Tameem Mohamed El-Khateeb**, Lecturer of Orthopedic Surgery, Faculty of Medicine – Ain Shams University, for his beneficial guidance, valuable remarks, keen supervision and moral support throughout this work,*

Khalid Nabil Youssef





بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
"فَالِقُ فَضْلُ اللَّهِ"
يَهْتِلُهُ مَنْ يَخْلُقُ وَاللَّهُ
فِيهِ الْفَضْلُ الْعَظِيمُ

صَدَقَ اللَّهُ الْعَظِيمُ
(سورة الجمعة)
"ايه (٤)"

LIST OF CONTENTS

	Page
List of Abbreviations	I
List of Tables	II
List of Figures	III
Abstract	- -
Introduction	1
Aim of the Work	3
Materials and Methods	4
Biomechanics of Osteoporotic Fractures	7
Assessment of the Results from Data Base Search...	30
Discussion	79
Conclusion	83
References	84
Arabic Summary	- -

LIST OF ABBREVIATION

BMD	Bone Mineral Density
CI	Confidence interval
DANCE	Direct Assessment of Nonvertebral Fractures in Community Experience
DEXA	Dual-energy X-ray absorptiometry
FPT	Fracture Prevention trial
FRAX	Fracture Risk Assessment Tool
MORE	multiple outcomes for raloxifene evaluation
NVFX	nonvertebral fragility fractures
rhPTH	recombinant human parathyroid hormone
RR	Relative risk
SD	Standard deviation
TOWER	Teriparatide Once-Weekly Efficacy Research

LIST OF TABLES

No.	Table	Page
1-	<i>Relative risk of new vertebral fracture in relation to prior vertebral fractures</i>	26
2-	<i>Summary of the results of the electronic data base search</i>	34
3-	<i>The non vertebral fractures as defines through different trials</i>	51
4-	<i>Summary of non vertebral fractures with Alendronate versus TPTD</i>	61
5-	<i>Incidence of Vertebral Fractures in PWM with osteoporosis after treatment with teriparatide or comparator</i>	64
6-	<i>Incidence of Nonvertebral Fractures in PWM with osteoporosis after treatment with teriparatide or comparator</i>	66
7-	<i>Changes in the risk of development of both vertebral and non vertebral fractures</i>	69
8-	<i>Changes in Bone Mineral density associated with treatment with Teriparatide</i>	71
9-	<i>Reported Adverse events with treatment with teriparatide</i>	78

LIST OF FIGURES

No.	Figure	Page
1-	<i>PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram for study selection</i>	6
2-	<i>Etiology of age related fractures</i>	7
3-	<i>Stratigies to reduce fracture risk</i>	8
4-	<i>Determinants of whole bone strength</i>	11
5-	<i>Influence of bone geometry on BMD and compressive and bending strength</i>	13
6-	<i>Difference in medullary and periosteal expansion between both sex, with aging process</i>	13
7-	<i>Age-related changes in bone</i>	16
8-	<i>The incidence of fractures of vertebrae, hip, and wrist rises progressively after menopause</i>	17
9-	<i>Internal architecture of a lumbar vertebra</i>	18
10-	<i>The mechanism of weight transmission in an intervertebral disc</i>	21
11-	<i>Degenerative disc disease alters compression loads on vertebrae</i>	23
12-	<i>Three types of vertebral compression fracture</i>	25
13-	<i>Vertebral fracture predicts future vertebral fractures</i>	27
14-	<i>Effect of fractures on compressive loading across the spine</i>	29
15-	<i>Incidence of new fractures during the 72-wk study period</i>	37
16-	<i>Demographics of subjects in the follow up study</i>	39
17-	<i>Incidence of new vertebral fractures during the 1 year follow up period (Lt) & cumulative incidence from the start of the original TOWER trial (RT)</i>	40
18-	<i>Incidence of new vertebral fractures during the study period</i>	42

LIST OF FIGURES

No.	Figure	Page
19-	<i>The cumulative incidence of one or more new non vertebral fractures</i>	44
20-	<i>Number of patients with new vertebral fracture during follow up study and relative risk</i>	45
21-	<i>The effect of teriparatide on the risk of new vertebral fractures</i>	46
22-	<i>New vertebral fractures in placebo and 20 ug teriparatide by increasing prevalent and severity of fractures</i>	47
23-	<i>Proportion of women with incident vertebral fractures by number of prevalent vertebral fractures</i>	49
24-	<i>Proportion of patients experiencing non vertebral fragility fractures and vertebral fracture</i>	50
25-	<i>Non vertebral fractures from the all non vertebral</i>	52
26-	<i>Cumulative proportion of women enrolled in follow up study who had one or more nonvertebral fragility fractures after baseline</i>	55
27-	<i>Incidence of new nonvertebral fractures in patient treated with teriparatide and after treatment cessation for entire DANCE trial</i>	57
28-	<i>Incidence of new Nonvertebral fractures in patients treated with teriparatide and after treatment cessation in those with and without prior vertebral fracture</i>	58
29-	<i>Incidence of vertebral fracture (a), and nonvertebral fractures (b) in patients with osteoporosis at high risk of fracture, during treatment with teriparatide</i>	63
30-	<i>Incidence of vertebral fracture with teriparatide treatment in PMW with osteoporosis</i>	65
31-	<i>Incidence of non vertebral fracture with teriparatide treatment in PWM with osteoporosis</i>	68

LIST OF FIGURES

No.	Figure	Page
32-	<i>Changes in the risk of development of both vertebral and non vertebral fractures</i>	70
33-	<i>Changes in BMD with teriparatide treatment in FPT</i>	73
34-	<i>Changes in BMD with teriparatide treatment in TOWER trial</i>	74
35-	<i>Changes in BMD with teriparatide treatment in Miyauchi A</i>	75
36-	<i>Changes in BMD with teriparatide treatment in comparison to Alendronate (Body).</i>	76
37-	<i>Changes in BMD with teriparatide treatment (Nishikawa)</i>	77
38-	<i>3D CT reconstructions of a paired iliac crest bone biopsy</i>	81

Abstract

Background : Teriparatide , a synthetic parathyroid hormone ,increase the bone formation and bone mass . The known regimen is 20 mcg /day, through the subcutaneous injection. **Method :** Searching electronic database for its effect on prevention of both vertebral and non-vertebral fractures among postmenopausal women with osteoporosis . **Results :** Through 23 results, following the inclusion criteria , incidence of both vertebral and non-vertebral fractures was significantly decreased with teriparatide treatment , with different dosage (20mcg/day , 56.5 mcg/week and 28.2 mcg/week) . **Conclusion :** teriparatide decrease the risk of both vertebral and non-vertebral fractures among postmenopausal women with osteoporosis , and the effect on vertebral fractures being higher.

Keywords: Teriparatide , postmenopausal osteoporosis , vertebral fracture , non-vertebral fractures , incidence of fracture ,

INTRODUCTION

In 2001, the National Institutes of Health Consensus Development Panel on Osteoporosis issued a consensus definition of osteoporosis: 'Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture' (*Lorentzon, 2015*).

According to WHO, it could be defined as a decrease in bone mineral density by more than 2.5 standard deviation below mean value of adult (*Parveen et al., 2005*). Among different causes of osteoporosis, postmenopausal osteoporosis is being the most common (*Colledge et al., 2010*). In modern Egypt, it has been estimated that 53.9% of postmenopausal women have osteopenia and 28.4 have osteoporosis (*Mohy, 2011*).

The clinical importance of osteoporosis lies in the fact that it is a risk factor for fractures and the risk of fracture increase by a factor of 1.5 to 3 folds for each SD reduction in BMD (*Court Brown et al., 2014*). Fractures related to osteoporosis are estimated to affect around 30% of women and 12 % of men at same point in developed countries (*Colledge et al., 2010*).

Osteoporotic fractures can affect any bone but the most common sites are spine, hip and forearm (Colle's) and hip fractures are the most serious (*Colledge et al., 2010*).

Approximately 30% of women sustain a vertebral fracture by age of 70th and 50% by age of 85 years old (***Bouxsein et al., 2009***).

The main goal of osteoporosis therapy is to reduce fracture risk (***Gallager et al., 2006***). Several drugs have been shown to reduce the risk of osteoporotic fractures in randomized controlled trials, including both vertebral and non-vertebral fractures (***Colledge et al., 2010***).

Teriparatide [rhPTH (1-34), TPTD] is the only bone forming drug approved by the US Food and Drug Administration for treatment of men and postmenopausal women with osteoporosis at high risk for fracture (***Gennant et al., 2005; Silverman et al., 2013***). Treatment with subcutaneous daily injections of teriparatide induces new bone formation by increasing the rate of bone remodeling, trabecular connectivity, and cortical bone thicken (***Dempster et al., 2001; Jiang et al., 2003; Compton, 2007***). Teriparatide improves the biomechanical properties of bone (***Keaveny et al., 2007***).

AIM OF THE WORK

A systematic review of literature to compare the results of usage of teriparatide for prevention of both osteoporotic vertebral and non-vertebral fractures in postmenopausal women.

MATERIALS AND METHODS

a- Search strategy: (fig1)

A literature search of the electronic databases of PUBMED (1995-July 2016) was conducted, using the following keywords “Teriparatide”, “vertebral fracture”, “non-vertebral fracture” and “postmenopausal osteoporosis” were used. The search was developed, conducted and was last updated in July 2016.

b- Criteria for selecting studies for this review:

1. Types of included studies:

- Published studies from 1995 – July 2016
- Published randomized controlled trials, Prospective studies.
- Written in English language only.
- Human studies only.

2. Types of excluded studies:

- Animal studies
- In Vitro studies
- Studies include in related surgical interference
- Studies related to the usage of teriparatide for treatment of non union or acceleration of healing process.
- Studies on male patients only.
- Pilot study.